Cancer treatment maker BioCold Genesys lands $22M in funds
March 18, 2019 at 17:22 PM EDT
Cold Genesys, Inc., a biopharmaceutical company developing novel immunotherapies used to treat cancer, has closed on $22 million in financing.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|